According to the NIAID fact sheet on Botulism, """"""""the extreme toxicity of botulinum neurotoxins (BoNT) and the ease of production, transport, and delivery make this an agent of extreme bioterrorism concern."""""""" Nonetheless, although there are major vaccine development initiatives ongoing, there currently is no approved Botulinum toxin vaccine available. Advances in Botulinum research have designated the optimal target for vaccine development to be the non-toxic carboxyterminal half of the toxin heavy chain (HC50). In fact, an immediate research goal for NIAID is listed as the development of a HC50 fragment vaccine against botulinum. Building upon the encouraging data from the phase I proof of concept study of this project, the overall phase II project goal is to develop a new, trivalent botulinum vaccine against the most common serotypes A, B and E.
Three Aims are proposed for the further development of this novel trivalent BoNT vaccine as follows:
Specific Aim 1 : Vaccine vector construction and recovery. i) plasmid constructions, ii) demonstration of cell surface expression of the BoNT HC50, and iii) re-recovery of recombinant RVs from cDNA on Vero.
Specific Aim 2. Vaccine vector characterization i) purification, inactivation, and in vitro characterization of the RV virions, ii) analysis of mouse immune responses to the vaccine using ELISA, in vitro neutralization assays, and in vivo protection of mice against a single challenge with BoNT or multiple BoNT challenge dependent on the used vaccine(s) for immunization.
Specific Aim 3 : Development of Pilot Production and Purification Processes. The overall goal of this aim is to translate the production process of our vaccine from a research setting to one suitable for pilot scale vaccine manufacture.
This research project is directly relevant to public health in that it is directed towards the development of a safe and effective vaccine for Botulinum neurotoxin. Botulinum toxin posesa major bioweapon threat because of its extreme potency andlethality and its ease of production and transport. A current investigational botulinum- toxoid vaccine requires multiple boosts to generate titers that are not very high, highlighting the need for an improved botulinum toxin vaccine. It is unclear if the current Botulinum vaccine protects at all as indicated by the disclaimer on the CDC vaccine consent form: ..., but other personal protective measures are still required. You should think of personal protective measures as the only protective measure against any of these bacteria (sic) toxins at this time.
|da Fontoura Budaszewski, Renata; Hudacek, Andrew; Sawatsky, Bevan et al. (2017) Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens. J Virol 91:|
|Davis, Benjamin M; Rall, Glenn F; Schnell, Matthias J (2015) Everything You Always Wanted to Know About Rabies Virus (But Were Afraid to Ask). Annu Rev Virol 2:451-71|
|Pfaller, Christian K; Cattaneo, Roberto; Schnell, Matthias J (2015) Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics. Virology 479-480:331-44|
|Hudacek, Andrew W; Al-Saleem, Fetweh H; Willet, Mallory et al. (2014) Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo. Mol Ther Methods Clin Dev 1:14046|
|Mustafa, Waleed; Al-Saleem, Fetweh H; Nasser, Zidoon et al. (2011) Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge. Vaccine 29:4638-45|